Author

Henry Long

Harvard University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Alan D. D’AndreaiD· 1 shared Alok K. TewariiD· 1 shared Buraq AhmediD· 1 shared Christian AlfieriiD· 1 shared Esmé Wheeler· 1 shared Eva CoreyiD· 1 shared Feng LuiD· 1 shared Myles A BrowniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan D. D’AndreaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer

Nicole A. Traphagen, Esmé Wheeler, Rong Li, Tara K. Akhshi, Ramya Ravindranathan, Christian Alfieri, Feng Lu, Buraq Ahmed, Alok K. Tewari, Steven P. Balk, Peter S. Nelson, Eva Corey, Henry Long, Alan D. D’Andrea, Xintao Qiu, Myles A Brown

This study shows that AR inhibition does not enhance PARP inhibitor efficacy in HR-proficient prostate cancer and instead impairs response in castration-sensitive cells.

Proceedings of the National Academy of Sciences · Jan 27, 2026Peer-reviewedCancer Biology